Myricx Bio
Myricx Bio invented a new kind of cancer-killing payload, which blocks an enzyme tumour cells need to survive, and attaches it to antibodies that carry it into tumours. Novartis bought the London company in 2026 for 1.1 billion dollars up front.
Overview
Myricx Bio (trading name of Myricx Pharma Limited, London, with a US office in Boston) developed a novel class of antibody-drug conjugate payloads based on inhibitors of N-myristoyltransferase (NMT), an enzyme required for the function of many proteins that cancer cells depend on. NMTi payloads are intended to overcome resistance to established payload classes such as topoisomerase 1 inhibitors, and preclinical data showed activity across solid tumour models including TOPO-1 resistant ones. The company's two lead ADC assets are directed at B7-H3 and HER2 and were preclinical at the time of the deal. Novartis agreed on 6 July 2026 to acquire Myricx for USD 1.1 billion upfront plus up to USD 400 million in milestones; the company's website states it became an indirect wholly owned Novartis subsidiary on 28 August 2026.
Funding
All startupsInvestors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · USD 1.1 billion upfront plus up to USD 400 million in milestones; agreement announced 6 July 2026, completed 28 August 2026 per company website | 2026 | $1.1B | novartis.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Pages like this
not linked directly; found by shared links- CompanyDuality Biotherapeutics
- CompanyIksuda Therapeutics
Shares HER2, Antibody-drug conjugate (ADC).
- PersonBob T. Li
Shares HER2, Antibody-drug conjugate (ADC).
- IdeaAlpha radioligands after ADC failure
Shares B7-H3, HER2, Antibody-drug conjugate (ADC).
- ProductTrastuzumab duocarmazine
Shares HER2, Antibody-drug conjugate (ADC).
- TermOverexpression
Shares B7-H3, HER2, Antibody-drug conjugate (ADC).
- CompanyDantari
Shares HER2, Antibody-drug conjugate (ADC).
- IdeaRe-map the tumour's surface proteins before choosing the next antibody drug
Shares B7-H3, HER2, Antibody-drug conjugate (ADC).